Featured Drug Company Program

Merck Helps


Merck Access Program


Merck Helps offers a full suite of support services that facilitate access to Merck’s drugs for eligible patients who are unable to afford their Merck medications, regardless of their insurance status.

Merck’s support services include the Merck Access Program (MAP), Merck Patient Assistance Program (MPAP), and the ACT Program.

Merck Access Program
The MAP provides eligible patients with access and support services, including insurance coverage for patients; benefits investigations, prior authorizations, and appeals; reimbursement; copay assistance for eligible patients; as well as referrals to MPAP.

ACT Program
The ACT Program offers similar support services as MAP for Noxafil (posaconazole).

Merck Patient Assistance Program
Eligible uninsured patients or those whose insurance does not cover their prescribed Merck medication may qualify to receive medication free of charge through MPAP.

Merck Co-pay Assistance Program
This program is available for patients with private health insurance who need assistance paying their copays that provides coverage for the prescribed Merck oncology medication—Keytruda (pembroliz­umab), Intron A for injection (interferon alfa-2b, recombinant), or Sylatron (peginterferon alfa-2b).

For more information visit Merck Helps at For a list of oncology and oncology supportive care drugs see the Table.

Table Merck Oncology/Supportive Care Drugs
Drug Indications Patient support programs Contact information
Emend capsules
Nausea and vomiting caused by chemotherapy Merck Access Program
Emend for injection
(fosaprepitant dimeglumine)
Nausea and vomiting caused by chemotherapy Merck Access Program
Merck Patient Assistance Program
Intron A
(interferon alfa-2b, recombinant) for injection
Hairy-cell leukemia, melanoma, follicular lymphoma, AIDS-related Kaposi’s sarcoma Merck Access Program
Merck Co-pay Assistance Program
Merck Patient Assistance Program
Unresectable or metastatic melanoma, metastatic non–small-cell lung cancer, recurrent or metastatic head and neck squamous-cell carcinoma that is progressing with or after platinum-containing chemotherapy Merck Access Program
Merck Co-pay Assistance Program
Merck Patient Assistance Program
Invasive Aspergillus and Candida infections in patients with hematologic cancer or those who underwent stem-cell transplantation Merck Access Program
ACT Program
(peginterferon alfa-2b)
Melanoma Merck Access Program
Merck Co-pay Assistance Program
Merck Patient Assistance Program


Merck Patient Assistance Program

Patients may qualify for MPAP, if:

  • They are legal residents of the United States or its territories
  • They have a prescription for a Merck medication from a licensed US healthcare provider
  • They are uninsured and/or do not have other forms of coverage for their prescription medicines
  • They are unable to afford their medication; the patient’s household income must be $58,850 or less for individuals, $79,650 or less for couples, or $121,250 or less for a family of 4.
Please contact the individual programs directly for specifics on the financial eligibility requirements for the programs.

MAP’s services are drug-­specific for Emend for injection (fosaprepitant dimeglumine), Emend capsules (aprepitant), Intron A for injection, Keytruda, or Sylatron. Visit or call 855-257-3932 for more information.

Merck Co-pay Assistance Program

The Merck Co-pay Assistance Program is available for patients:

  • Who are aged >18 years
  • Who have been prescribed a qualified Merck medication for an FDA-approved indication (Keytruda, Intron A, or Sylatron)
  • With private health insurance that provides coverage for the prescribed medication
  • Who meet certain financial ­requirements.
This program is not valid for patients covered under a government-funded program or uninsured patients. Patients must pay the first $50 of copay per administration of their drug, up to a maximum of $2500 per patient per calendar year.

Application & Enrollment

To enroll in MAP and/or MPAP programs, including the Merck Co-pay Assistance Program, patients in collaboration with their healthcare provider must complete the relevant sections of the enrollment form (available at, and fax it to 855-755-0518 or mail it to the address provided on the form.

The prescribed Merck medication (Intron A, Emend injection, Emend capsules, Keytruda, or Sylatron) and the program the patient is applying for must be indicated on the form. The patient’s insurance information and clinical information (including a diagnostic code) must be included.

The patient’s gross household income (including before-tax wages, pension, interest/dividends, Social Security benefits, and any other sources of income) must be supplied if the patient is applying for MPAP or the Merck Co-pay Assistance Program. Patients who qualify for the program are eligible to receive their medications at no cost for up to 1 year.

The ACT Program patient enrollment form is available at After the form has been completed, it must be faxed to 866-363-6389.

For more information on enrollment in the ACT Program, call 866-363-6379. A copy of the patient’s current prescriptions with complete directions and refills for Noxafil must be included with the application; financial enrollment is not required.